

Support for the amendment to page 7 is found, *inter alia*, in claim 1 as originally filed. Additional support for amino or carboxyl protected forms is found, *inter alia*, at specification page 13 (lines 17-19). Additional support for an admixture with a pharmaceutically acceptable carrier is found, *inter alia*, at specification page 16, line 7.\

Support for a derivative of a fragment of GLP-1 (1-37) having at least 80%, 90% or 95% of its amino acids the same as that of a fragment of GLP-1(1-37) that has the same number of amino acid residues as the derivative is found, *inter alia*, at page 5 (lines 2-18) and at page 12 (lines 7-11).

Support for a derivative in which a hydrophobic amino acid residues of GLP-1 (7-37) has been substituted with a different hydrophobic amino acid residue is found, *inter alia*, at specification page 13 (first paragraph).

Support for a derivative in which a basic amino acid residues of GLP-1 (7-37) has been substituted with a different basic amino acid residue is found, *inter alia*, at specification page 13 (first paragraph).

Support for a derivative in which an aromatic amino acid residues of GLP-1 (7-37) has been substituted with a different aromatic amino acid residue is found, *inter alia*, at specification page 13 (first paragraph).


Conclusion

Based on the amendments and remarks above, Applicant respectfully submits that the application is in condition for allowance. Early notice to this effect is earnestly solicited. If the Examiner believes, for any reason, that personal communication will

expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicant
Registration No. 33,851

Date: Dec. 18, 2000

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005
(202) 371-2600